Mylan Launches Generic Faslodex Injection for the Expansion of its Oncology Portfolio in the US

Shots:

• Mylan launches Fulvestrant Injection (50 mg/mL)/single-dose prefilled syringe which is a generic version of AstraZeneca’s Faslodex Injection and has received FDA’s ANDA as monothx. for advanced BC in women with menopause and combination therapy for advance & m-BC
• The launch of Fulvestrant Injection expands Mylan’s oncology portfolio and available treatment options for women facing advanced/m-BC
• Fulvestrant Injection is a prescription therapy used to treat multiple forms of advanced breast cancer and has generated ~$550M in 12mos. ending Jun 30, 2019

Click here to­ read full press release/ article | Ref: Mylan | Image: WSJ